Monitoring anticoagulant therapy with new oral agents  

作　　者：Allan Ramos-Esquivel 

机构地区：[1]Department of Pharmacology, School of Medicine, University of Costa Rica

出　　处：《World Journal of Methodology》2015年第4期212-215,共4页世界方法学杂志

摘　　要：Thromboembolic disease is a major leading cause of mortality and morbidity in industrialized countries. Currently, the management of these patients is challenging due to the availability of new drugs with proven efficacy and security compared to traditional oral vitamin K antagonists. These compounds are characterized by a predictable pharmacokinetic profile for which blood monitoring is not routinely needed. Nevertheless, some data have suggested inter-patient variability in the anticoagulant effect of these drugs, raising concerns about their effectiveness and safety. Although mass-spectrometry is the gold standard to determine drug plasma concentrations, this method is not widely available in every-day practice and some coagulation assays are commonly used to determine the anticoagulant effect of these drugs. The present review aims to summarize the current knowledge regarding the clinical question of how and when to monitor patients with new anticoagulant oral agents.Thromboembolic disease is a major leading cause ofmortality and morbidity in industrialized countries. Currently,the management of these patients is challenging dueto the availability of new drugs with proven efficacy andsecurity compared to traditional oral vitamin K antagonists.These compounds are characterized by a predictablepharmacokinetic profile for which blood monitoring is notroutinely needed. Nevertheless, some data have suggested inter-patient variability in the anticoagulant effect of these drugs, raising concerns about their effectiveness and safety. Although mass-spectrometry is the gold standard to determine drug plasma concentrations, this method is not widely available in every-day practice and some coagulation assays are commonly used to determine the anticoagulant effect of these drugs. The present review aims to summarize the current knowledge regarding the clinical question of how and when to monitor patients with new anticoagulant oral agents.

关 键 词：ANTICOAGULANT agents APIXABAN DABIGATRAN DRUG MONITORING RIVAROXABAN 

分 类 号：O1[理学—数学]